Market research
INDSWFTLAB.NSE Ind-Swift Laboratories Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 28B
- P/E ratio
- 50.12
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.71
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE915B01019
- Market cap
- 28B
- P/E ratio
- 50.12
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.71
About
About Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimuscarinic, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company exports its products. Ind-Swift Laboratories Limited was incorporated in 1995 and is based in Manimajra, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the INDSWFTLAB.NSE discussion.
5 years, 4 months ago
Ind-Swift Laboratories Limited is currently in a long term uptrend where the price is trading 30.9% above its 200 day moving average.
From a valuation standpoint, the stock is 87.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.6.
Ind-Swift Laboratories Limited's total revenue rose by 11.1% to $2B since the same quarter in the previous year.
Its net income has increased by 228.0% to $115M since the same quarter in the previous year.
Finally, its free cash flow fell by 5.0% to $549M since the same quarter in the previous year.
Based on the above factors, Ind-Swift Laboratories Limited gets an overall score of 4/5.